Navigation Links
HistoRx Announces Launch of New Research Services: AQUAPrep™ and Access AQUA® Services Now Available
Date:5/3/2011

BRANFORD, Conn., May 3, 2011 /PRNewswire/ -- HistoRx, Inc., announced today the launch of two new services for academic researchers interested in using AQUA® technology.  HistoRx's proprietary technology enables in situ analysis of biomarkers, including measurement of protein concentration with sub-cellular resolution in both whole tissue sections and tissue microarrays.  These highly quantitative, standardized and reproducible results take the guesswork out of IHC.

HistoRx provides AQUA analysis services for academic researchers interested in precise, accurate and reproducible protein expression quantification for their whole tissue or tissue microarray projects, giving researchers access to AQUA analysis without the cost of instrument purchase.  Academic scientists who want to use AQUA technology today have to buy a fluorescent digital microscopy system to acquire the images to be analyzed.  HistoRx recognizes that researchers often need high-quality data prior to the availability of funds for equipment purchase, such as proof-of-concept or grant support studies, and HistoRx wants to enable the expansion of AQUA technology's use into new areas.

"We've received several requests from universities to conduct one-time studies, or a short series of investigations, on their behalf for grant support," said Mark Gustavson, Assistant Director of Operations at HistoRx.  "AQUA analysis is a powerful tool and we want to ensure the widest possible access.  Providing the rigorous data to support development of new biological insights and clarify the benefits of a lab's eventual equipment purchase is in everyone's best interests."

In the Access AQUA® services program HistoRx will stain an investigator's slides, acquire digital fluorescent images, perform AQUA analysis, and provide the researcher with the images and the AQUA scores for the biomarkers of their choice.  This program is ideal for those conducting one or two experiments, or to demonstrate proof of concept for a grant application.

AQUAPrep™ services are tailored for those with several experiments in mind: the academic laboratory purchases a copy of AQUA software from HistoRx, HistoRx stains the slides, acquires digital fluorescent images, and sends the data files to the researcher for their own analysis using AQUA software.  This program enables researchers and their staff to become familiar with the use of the AQUAnalysis™ program prior to making an instrument investment.

AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.  Such precise determination of first, the location within the tumor cell and second, the amount in each location is not possible with any other method, digital or otherwise.  AQUA analysis is used in cancer research by over twenty leading academic centers worldwide, is part of the clinical development plans for more than ten drug candidates from major pharma companies, and has been cited in more than 90 peer-reviewed publications.  The first use of AQUA technology in the clinical diagnostic setting occurred in 2010 with the launch by Genoptix Inc. (a subsidiary of Novartis) of diagnostic tests based on AQUA technology licensed from HistoRx. AQUA technology is currently available on the ScanScope FL™ from Aperio and will be available later this year on the Nuance™ and Vectra™ systems from Caliper Life Sciences.

About HistoRx, Inc.

HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care.  The company's products and services are based on proprietary analysis of tissue biomarkers using AQUA® technology.  AQUA® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making.  HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care.  For more information, please visit www.historx.com.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
3. HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology
4. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
5. HistoRx Receives Fundamental Patent on Standardization of Results In Digital Pathology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):